ArticleScientific reports2025
Modeling antibody persistence after MenACYW-TT vaccination and comparative analysis with other quadrivalent meningococcal vaccines.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mass Gatherings as Amplifiers of Meningococcal Disease: A Modeling Study of Hajj and Umrah.Infectious diseases and therapy · 2026Article
- Podcast: Immune Persistence After Primary Vaccination with MenQuadfi.Infectious diseases and therapy · 2026Review
- Persistence of Serum Bactericidal Antibody in the First 2-Years After Immunization with Pentavalent Meningococcal ACWYX Vaccine in Malian Infants and Toddlers.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evaluating the persistence of antibody titers produced by quadrivalent meningococcal vaccines is crucial for determining the optimal timing for primary and booster doses. Using 3 - 7-year persistence data after a single priming dose of MenACYW-TT to fit a statistical model of antibody decay over time (10 years), this analysis modeled long-term antibody persistence for this vaccine in toddlers (12-23 months), adolescents/young adults (13-26 years), and older adults (≥ 56 years), comparing it with other vaccines (MCV4-TT, MenACWY-CRM, MPSV4). The statistical model is based on a Bayesian approach and it accounts for vaccine- and age group-specific antibody decline, missing data, assay errors, and antibody boosting from breakthrough infections. At 10 years post-vaccination, it predicted comparable or higher seroprotective immunopersistence for MenACYW-TT (titers ≥ 1:8 with hSBA) versus (1) MCV4-TT in toddlers (77% [95% CI 70-84] vs. 17% [6-31] for serogroup C, 67% [59-74] vs. 36% [20-53] for serogroup W); (2) MenACWY-CRM in adolescents/young adults (63% [55-71] vs. 40% [32-48] for serogroup C, 67% [59-74] vs. 57% [47-67] for serogroup W); and (3) MPSV4 in older adults (31% [23-39] vs. 22% [14-29] for serogroup C, 38% [31-46] vs. 20% [14-27] for serogroup W). In conclusion, our analysis indicated similar or higher immune persistence at 10 years for MenACYW-TT compared with other quadrivalent meningococcal vaccines, particularly for serogroups C and W.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.